期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

苯达莫司汀在淋巴肿瘤中的应用进展 被引量：4

原文传递
导出
摘要 苯达莫司汀（Bendamustine）是一种兼具烷化剂和抗代谢作用的细胞毒药物,该药在多种血液系统肿瘤和实体瘤中显示了良好疗效.临床以及体外实验显示,其与烷化剂等少有交叉耐药.苯达莫司汀单药或联合利妥昔单抗目前已经成为CLL初治以及复发患者的一线治疗方案.对于利妥昔单抗复发耐药的患者,其总反应率90%～92%,完全缓解率55%～60%.该药耐受性良好,不良反应主要为可逆性骨髓抑制.然而目前仍存在若干亟待解决的问题,如苯达莫司汀最佳治疗剂量以及疗程、该药对于中重度肝肾功能不全患者的影响、该药治疗对于干细胞运输以及采集的影响、与继发性MDS之间的关系等.
作者 邢立杰(综述) 李增军(审校) 邱录贵(审校)
机构地区 中国医学科学院、北京协和医学院血液学研究所、血液病医院
出处 《国际输血及血液学杂志》 CAS 2011年第1期24-27,共4页 International Journal of Blood Transfusion and Hematology
基金 国家科技支撑计划项目（2008BA161B01）,天津市科技支撑计划项目（09ZCGYSF01000）
关键词 苯达莫司汀 慢性淋巴细胞白血病/小淋巴细胞淋巴瘤 惰性非霍奇金淋巴瘤 套细胞淋巴瘤 多发性骨髓瘤 烷化剂
分类号 R733.4 [医药卫生—肿瘤]
  • 相关文献

参考文献19

  • 1Knauf WU,Lissichkov T,Aldaoud A,et al.Bendamustin eversus chlorambucil in treatment-naive patients with B-cell chronic lymphocytic leukemia (B-CLL):re-sults of an international phase Ⅲ study.Blood (ASH Annual Meeting Abstracts),2007,110:2043.
  • 2Knauf WU,Lissichkov T,Aldaoud A,et al.Phase Ⅲ Randomized Study of Bendamustine Compared With Chlorambucil in Previously Untreated Patients With Chronic Lymphocytic Leukemia.J Clin Oncol,2009,27 (26):4378-4384.
  • 3Knauf WU,Lissichkov T,Aldaoud A,et al.Bendamustine in the Treatment of Chronic Lymphocytic Leukemia -Consistent Superiority Over Chlorambucil in Elderly Patients and Across Clinically Defined Risk Groups.Blood (ASH Annual Meeting Abstracts),2009,114:2367.
  • 4Weide R,Pandorf A,Heymanns J,et al.Bendamustine/mitoxantrone/rituxi-mab (BMR):A very effective,well tolerated outpatient chemoimmunotherapy for relapsed and refractory CD20-positive indolent malignancies Final results of a pilot study.Leuk Lymphoma,2004,45 (12):2445-2449.
  • 5Fischer K,Cramer P,Stilgenbauer S,et al.Bendamustine Combined with Rituximab (BR) in First-Line Therapy of Advanced CLL:A Multicenter Phase Ⅱ Trial of the German CLL Study Group (GCLLSG).Blood (ASH Annual Meeting Abstracts),2009,114:205.
  • 6Kahl B,Bartlett NL,Leonard JP,et al.Bendamustine is effective therapy in patients with rituximab-refractory,indolent B-cell non-Hodgkin lymphoma.results from a Multicenter Study.Cancer,2010,116(1):106-114.
  • 7Michinori O,Toshiki U,Kiyoshi A,et al.Bendamustine Is Highly Effective for Relapsed or Refractory Indolent B-Cell NonHodgkin Lymphoma (B-NHL) and Mantle Cell Lymphoma (MCL):Final Results of a Japanese Multicenter Phase Ⅱ Study.Blood (ASH Annual Meeting Abstracts),2009,114:3694.
  • 8Cephalon Inc.(2008) Treanda (bendamustine hydrochloride for injection) for intravenous infusion:US prescribing information.Cephalon,Inc,Frazer.
  • 9Weide R,Hess G,Koppler H,et al High anti-lymphoma activity of benda-mustine/mitoxantrone/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas.A multicenter phase Ⅱ study of the German Low Grade Lymphoma Study Group(GLSG).Leuk Lymphoma,2007,48(7):1299-1306.
  • 10Fowler N,Brad S Kah,Rosen P,et al.Bortezomib,Bendamustine,and Rituximab in Patients with Relapsed or Refractory Follicular Lymphoma:Encouraging Activity in the Phase 2 VERTICAL Study,Blood (ASH Annual Meeting Abstracts),2009,114:933.

同被引文献70

  • 1Schrijvers D, Vermorken JB. Phase I studies with bendamustine: an update. Semin Oncol, 2002, 29(4 Suppl 13) : 15-18.
  • 2Bremer K. High rates of long-lasting remissions after 5-day bendamustine chemotherapy cycles in pre-treated low-grade non- Hodgkin's-lymphomas. J Cancer Res Clin Oncol, 2002, 128 : 603- 609.
  • 3Kahl BS, Bartlett NL, Leonard JP, et al. Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non- Hodgkin lymphoma: results from a Multicenter Study. Cancer, 2010, 116: 106-114.
  • 4Ohmachi K, Ando K, Ogura M, et al. Multicenter phase II study of bendamustine for relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma. Cancer Sci, 2010, 101 : 2059- 2064.
  • 5Robinson KS, Williams ME, van der Jagt RH, et al. Phase U multieenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma. J Clin Oncol, 2008, 26: 4473-4479.
  • 6Ogura M, Ando K, Taniwaki M, et al. Feasibility and pharmacokinetic study of bendamustine hydrochloride in combination with rituximab in relapsed or refractory aggressive B cell non- Hodgkin's lymphoma. Cancer Sci, 2011, 102: 1687-1692.
  • 7Weide R, Hess G, Kappler H, et al. High anti-lymphoma activity of bendamustine/mitoxantrone/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas. A multicenter phase II study of the German Low Grade Lymphoma Study Group (GLSG). Leuk Lymphoma, 2007, 48: 1299-1306.
  • 8Visani G, Malerba L, Stefani PM, et al. BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients. Blood, 2011, 118 : 3419-3425.
  • 9Heider A, Niederle N. Efficacy and toxicity of bendamustine in patients with relapsed low-grade non-Hodgkin's lymphomas. Anticancer Drugs, 2001, 12: 725-729.
  • 10Knauf WU, Lissichkov T, Aldaoud A, et al. Phase 111 randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol, 2009, 27: 4378-4384.

引证文献4

二级引证文献7

国际输血及血液学杂志
2011年 第1期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部